An Observational Study of MabThera/Rituxan (Rituximab) Plus Chemotherapy As First-Line Treatment in Patients With Diffuse Large B-Cell Lymphoma or Follicular Lymphoma
- Conditions
- Diffuse Large B-Cell Lymphoma
- Registration Number
- NCT01340443
- Lead Sponsor
- Hoffmann-La Roche
- Brief Summary
This observational study will evaluate the safety and efficacy of MabThera/Rituxan (rituximab) plus chemotherapy as first-line treatment in patients with diffuse large B-cell lymphoma (DLBCL) or follicular lymphoma (FL). Data will be collected from each patient during the 6 months of induction treatment and for up to 3 years of follow-up.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 314
- Histologically confirmed CD20+ diffuse large B-cell lymphoma or follicular lymphoma
- Treatment with MabThera/Rituxan as per locally approved China package insert
- Documented patient with medical records
- Previous treatment for diffuse large B-cell lymphoma or follicular lymphoma
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Safety: Incidence of adverse events 4.5 years
- Secondary Outcome Measures
Name Time Method Overall Survival, defined as time from 1st treatment to death of any cause 4.5 years Overall Response Rate (complete response + partial response) 4.5 years Progression-free survival, defined as time from first treatment to lymphoma progression or death 4.5 years
Trial Locations
- Locations (24)
Xiangya Hospital of Centre-South University
🇨🇳Changsha, China
Lanzhou General Hospital, PLA Lanzhou Military Area Command
🇨🇳Lanzhou, China
the First Hospital of Jilin University
🇨🇳Changchun, China
Fujian Provincial Hospital
🇨🇳Fuzhou, China
The Affiliated Hospital of Military Medical Sciences(The 307th Hospital of Chinese PLA)
🇨🇳Beijing, China
The Second Affiliated Hospital of Zhejiang University College
🇨🇳Hangzhou, China
The affiliated Hospital of Guiyang Medical College
🇨🇳Guiyang, China
Jiangsu Cancer Hospital
🇨🇳Nanjing, China
Changzhou First People's Hospital
🇨🇳Changzhou, China
The First People's Hospital of Foshan
🇨🇳Foshan, China
Daqing Oilfield General Hospital
🇨🇳Daqing, China
Nanfang Hospital, Southern Medical University
🇨🇳Guangzhou, China
Fuzhou General Hospital, PLA Nanjing Military Area Command
🇨🇳Fuzhou, China
Anhui Province Cancer Hospital
🇨🇳Hefei, China
Affiliated Hospital of Inner Mongolia Medical College
🇨🇳Hohhot, China
The First Affilliated Hospital of Kunming Medical College
🇨🇳Kunming, China
Shanxi Province Cancer Hospital
🇨🇳Taiyuan, China
Shandong Cancer Hospital
🇨🇳Jinan, China
Hebei Medical University Fourth Hospital;(Tumor Hospital of Hebei Province)
🇨🇳Shijiazhuang, China
Xiehe Hospital, Tongji Medical College Huazhong University of Science & Technology
🇨🇳Wuhan, China
The Second Affiliated Hospital of The Fourth Military Medical University (Tangdu Hospital)
🇨🇳Xi'an, China
Henan Cancer Hospital
🇨🇳Zhengzhou, China
Zhongshan General Hospital
🇨🇳Zhongshan, China
The First Affiliated Hospital of Zhengzhou University
🇨🇳Zhengzhou, China